ABF Pharmaceutical Services GmbH announces the new appointment of President of Commercial Operations

ABF Pharmaceutical Services GmbH announces the appointment of Ms Maxime Stevens as President of Commercial Operations, tasked with the responsibility of strategically growing and aligning the Company, preparing the foundations for long-term growth, strategic excellence, and the expansion of new geographic opportunities.

Max has in excess of 25 years' experience in executive leadership, developing Global BD and Operations groups for both US and European companies, including United States Surgical Corporation, Cyberonics Inc., and SynteractHCR. She is an inspiring leader and mentor, widely respected and supported across the industry, and has impacted long-term growth, operational excellence, and the expansion of new geographic and channel opportunities for significant companies. Her extensive international experience, gained particularly in MENA, Africa, Europe and the US, is a valuable asset for ABF, and her passion for people, excellence and ethics can only enhance and further drive the already recognized success of this company.

The Company, alongside strong leadership, strategic focus and guidance will continue to drive forward process and delivery, excellence of service and quality, and commitment to our Sponsors.

About ABF Pharma:

ABF is a global CMO/Central Lab specialising in labelling and packaging of IMPs including central lab services, bio sample storage and QP release. ABF's flexible solutions include IMP import / export, label text compliancy, labelling and packaging, EU- Batch Releases and temperature controlled environment warehousing / transportation.

ABF also provides a one-stop solution central lab services including sourcing, patient kit assembling, logistic services and bio sample storage, and controlled drug storage and handling.
Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning ABF Pharmaceutical Services GmbH and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of ABF Pharmaceutical Services GmbH to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  ABF Pharmaceutical Services GmbH is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.